# BPC-157 Dosage in Research: Doses, Routes, and Half-Life

> How BPC-157 dosage is expressed in the research: rodent doses per body weight, the injection and oral routes studied, the human-pilot infusion amounts, and the animal half-life.

Research-context figures only — what was administered, to which species, by which route. No human protocol exists; the doses below are study readouts, not guidance.

## How BPC-157 Doses Are Expressed in the Research

BPC-157 dosage in the literature is expressed as a research figure tied to a species and a route — never as a human protocol, because no validated human protocol exists [6]. Rodent studies commonly express dose per body weight, frequently around `10 microg/kg` and `10 ng/kg`, and as low as `10 pg` in some tendon work [1]. Gastric-ulcer cytoprotection was studied at `400 ng/kg` and `800 ng/kg` in rats [4].

Human exposure data are minimal: a two-person intravenous safety pilot used `10 mg` then `20 mg` by infusion [5], and an interstitial-cystitis pilot used a single `10 mg` dose intravesically [8]. These are the amounts administered in specific studies — they are reported here so the literature can be read accurately, not as a recommendation for any person.

## BPC-157 Injection Routes Used in Studies

BPC-157 injection in research spans several routes. The most common in rodent work is intraperitoneal, used in the transected-Achilles tendon study at once-daily dosing [1]. Intramuscular and intragastric routes were directly compared in the gastric-ulcer model, where intramuscular delivery outperformed intragastric [4]. Local and intra-lesional administration has also been tested [1].

In humans, the three pilots used intravenous infusion [5], intravesical instillation during cystoscopy [8], and intra-articular injection into the knee [7]. Each route appears in a distinct study; none has an established human dose.

## BPC-157 Half-Life in Animal Pharmacokinetics

BPC-157's elimination half-life is reported as under `30 min` for the prototype peptide in a rat and dog pharmacokinetic study, after both intravenous and intramuscular administration [2]. The same study found linear pharmacokinetics and intramuscular bioavailability of roughly `14-19%` in rats and `45-51%` in dogs, with rapid breakdown into small peptide fragments [2]. There is no published human half-life for BPC-157.

## Why per-kilogram figures do not convert to a human dose

The recurring confusion online is treating a rodent `microg/kg` figure as if it scales cleanly to a person. It does not. The Achilles-tendon work used `10 microg`, `10 ng`, or `10 pg` per rat — a four-order-of-magnitude span that still produced effect [1] — which tells you the dose-response in that model is unusually wide, not that any single number is a human target. Interspecies scaling, route differences, and the short animal half-life all sit between a rat figure and a human exposure.

The two-tier evidence frame applies to dosing as much as to efficacy. The only human exposures on record are the pilot infusions of `10 mg` and `20 mg` IV [5] and the single `10 mg` intravesical dose [8] — fixed amounts chosen for those specific feasibility studies, not validated doses. The rodent `microg/kg` and `ng/kg` figures belong to the preclinical tier and stay there.

## Stability and reconstitution as research handling

BPC-157 is often supplied as a lyophilized acetate salt and reconstituted in a diluent for research handling. Its "stable gastric pentadecapeptide" name reflects reported stability in gastric juice, which underlies oral interest, though human oral pharmacokinetics remain unestablished [2]. Storage and reconstitution practices described in research settings are laboratory handling, not validated clinical protocols, and nothing on this page should be read as preparation instructions.

## How long should I stay on BPC-157?

Animal studies use defined dosing courses measured over days to weeks, not open-ended use. There is no validated human protocol for BPC-157, and a 2025 review urges treating it as investigational [6]. "How long to stay on it" therefore has no evidence-based answer for a person — only the fixed-duration designs of the preclinical studies.

---

A two-tier readout of the BPC-157 record — the human pilots logged above the animal evidence, sourced line by line, with no clinic behind the console and nothing here for sale.